Table 1 Summary of the randomized controlled trials (RCTs) included in this meta-analysis
Author | Year | Phase of the trial | Duration of therapy | Intervention arm-1 | Intervention arm-2 | Intervention arm-3 | Intervention arm-4 | Control arm |
|---|---|---|---|---|---|---|---|---|
Kremer JM et al. study 1[18] | 2012 | Phase IIb | 24-weeks | Tofacitinib 3-mg BID + Methotrexate (N = 68) | Tofacitinib 5-mg BID + Methotrexate (N = 71) | Tofacitinib 10-mg BID + Methotrexate (N = 74) | Tofacitinib 15-mg BID + Methotrexate (N = 75) | Placebo + Methotrexate (N = 69) |
Tanaka Y et al.[19] | 2011 | Phase II | 12-weeks | Tofacitinib 3-mg BID + Methotrexate (28) | Tofacitinib 5-mg BID + Methotrexate (N = 28) | Tofacitinib 10-mg BID + Methotrexate (N = 28) | .. | Placebo + Methotrexate (N = 28) |
Fleischmann R et al. study 1[16] | 2012 | Phase IIb | 24-weeks | Tofacitinib 3-mg BID (N = 51) | Tofacitinib 5-mg BID (N = 49) | Tofacitinib 10-mg BID (N = 61) | Tofacitinib 15-mg BID (N = 57) | Placebo (N = 59) |
Fleischmann R et al. study 2[11] | 2012 | Phase III | 6-months | .. | Tofacitinib 5-mg BID (N = 243) | Tofacitinib 10-mg BID (N = 245) | .. | Placebo (N = 122) |
Kremer JM et al. study 2[17] | 2009 | Phase IIa | 12-weeks | . | Tofacitinib 5-mg BID (N = 61) | .. | Tofacitinib 15-mg BID (N = 69) | Placebo (N = 65) |
Burmester GR et al.[10] | 2013 | Phase III | 6-months | … | Tofacitinib 5-mg BID + Methotrexate (N = 133) | Tofacitinib 10-mg BID + Methotrexate (N = 134) | .. | Placebo + Methotrexate (N = 132) |
van der Heijde D et al.[12] | 2013 | Phase III | 24-month | .. | Tofacitinib 5-mg BID + Methotrexate (N = 321) | Tofacitinib 10-mg BID + Methotrexate (N = 316) | .. | Placebo + Methotrexate (N = 160) |
van Vollenhoven RF et al.[13] | 2012 | Phase III | 12-month | .. | Tofacitinib 5-mg BID + Methotrexate (N = 204) | Tofacitinib 10-mg BID + Methotrexate (N = 201) | .. | Placebo + Methotrexate (N = 108) |